The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis
Phase I Study to Evaluate the Safety and Tolerance of RMP-7 Administered With Amphotericin B to Patients With HIV Infection and Cryptococcal Meningitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Los Angeles County - USC Med Ctr
-
Orange, California, United States, 92668
- UCI Med Ctr
-
San Diego, California, United States, 92103
- UCSD Treatment Ctr
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Univ of Kansas School of Medicine
-
-
New York
-
Stony Brook, New York, United States, 117948153
- SUNY / Health Sciences Ctr at Stony Brook
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Univ Med Ctr
-
Greenville, North Carolina, United States, 278584354
- East Carolina Univ School of Medicine
-
Winston Salem, North Carolina, United States, 271571042
- Bowman Gray School of Medicine
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve Univ
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Pennsylvania State Univ / Hershey Med Ctr
-
-
Texas
-
Galveston, Texas, United States, 775550882
- Univ TX Galveston Med Branch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed:
- Up to 1 mg/kg amphotericin B for the current episode of cryptococcal meningitis.
Patients must have:
- HIV infection.
- Acute cryptococcal meningitis.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Cardiovascular disorders including congestive heart failure, uncontrolled hypertension (seated diastolic blood pressure > 95 mm Hg), or symptomatic ischemic heart disease (angina).
- Orthostatic hypotension, defined as a decrease in systolic blood pressure of >= 20 mm Hg upon standing.
- Coma.
- Other CNS disease (e.g., other intracranial infections) that may interfere with assessment of response.
- Opening CSF pressure >= 350 mm or papilledema. (For patients with recurrent disease, evidence of mass effect on either MRI or CT excludes.)
- Any concurrent disease that would preclude participation in the study.
Patients with the following prior conditions are excluded:
- History of any bleeding disorder.
- History of active renal or hepatic disease.
- Myocardial infarction within the previous 3 months.
- Stroke within the previous 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: Double
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Central Nervous System Infections
- Bacterial Infections and Mycoses
- Mycoses
- Slow Virus Diseases
- Meningitis, Fungal
- Central Nervous System Fungal Infections
- Cryptococcosis
- HIV Infections
- Infections
- Acquired Immunodeficiency Syndrome
- Meningitis
- Meningitis, Cryptococcal
- Anti-Infective Agents
- Anti-Bacterial Agents
- Antifungal Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Amebicides
- Amphotericin B
- Liposomal amphotericin B
Other Study ID Numbers
Other Study ID Numbers
- 131A
- ALK01-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.